Coelho Inês, Duarte Nádia, Macedo Maria Paula, Penha-Gonçalves Carlos
CEDOC, NOVA Medical School, Faculdade de Ciências Médicas, Universidade Nova de Lisboa, 1150-082 Lisboa, Portugal.
Instituto Gulbenkian de Ciência, 2780-156 Oeiras, Portugal.
J Clin Med. 2021 Mar 17;10(6):1248. doi: 10.3390/jcm10061248.
Liver disease accounts for millions of deaths worldwide annually being a major cause of global morbidity. Hepatotoxic insults elicit a multilayered response involving tissue damage, inflammation, scar formation, and tissue regeneration. Liver cell populations act coordinately to maintain tissue homeostasis and providing a barrier to external aggressors. However, upon hepatic damage, this tight regulation is disrupted, leading to liver pathology which spans from simple steatosis to cirrhosis. Inflammation is a hallmark of liver pathology, where macrophages and endothelial cells are pivotal players in promoting and sustaining disease progression. Understanding the drivers and mediators of these interactions will provide valuable information on what may contribute to liver resilience against disease. Here, we summarize the current knowledge on the role of macrophages and liver sinusoidal endothelial cells (LSEC) in homeostasis and liver pathology. Moreover, we discuss the expanding body of evidence on cell-to-cell communication between these two cell compartments and present triggering receptor expressed on myeloid cells-2 (Trem-2) as a plausible mediator of this cellular interlink. This review consolidates relevant knowledge that might be useful to guide the pursue of successful therapeutic targets and pharmacological strategies for controlling liver pathogenesis.
肝病每年在全球导致数百万例死亡,是全球发病的主要原因。肝毒性损伤引发了包括组织损伤、炎症、瘢痕形成和组织再生在内的多层次反应。肝细胞群协同作用以维持组织稳态,并对外来侵害者提供屏障。然而,肝脏受损时,这种严格的调节被破坏,导致肝脏病变,范围从单纯脂肪变性到肝硬化。炎症是肝脏病变的一个标志,其中巨噬细胞和内皮细胞是促进和维持疾病进展的关键因素。了解这些相互作用的驱动因素和介质将为哪些因素可能有助于肝脏抵抗疾病提供有价值的信息。在此,我们总结了目前关于巨噬细胞和肝窦内皮细胞(LSEC)在稳态和肝脏病变中的作用的知识。此外,我们讨论了关于这两个细胞区室之间细胞间通讯的越来越多的证据,并提出髓系细胞表达的触发受体2(Trem-2)作为这种细胞间联系的一个可能介质。这篇综述整合了相关知识,可能有助于指导寻找成功的治疗靶点和控制肝脏发病机制的药理学策略。